Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

This publication has 44 references indexed in Scilit:

• A prospective randomised study in limited disease small cell carcinoma—Doxorubicin and vincristine plus either cyclophosphamide or etoposide
  European Journal Of Cancer, 1995
• Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
  Journal of Clinical Oncology, 1995
• Quality-of-life and cost-effectiveness assessment in lung cancer
  Current Opinion in Oncology, 1995
• Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission
  JNCI Journal of the National Cancer Institute, 1995
• Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1995
• A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
  Journal of Clinical Oncology, 1994
• Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer
  New England Journal of Medicine, 1993
• Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin
  British Journal of Haematology, 1993
• Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony- stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin [see comments]
  Blood, 1992
• Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
  Journal of Clinical Oncology, 1990